Aduro Biotech Names Industry Veteran And Academic Leader, Gerald Chan, DSc To Its Board Of Directors

Aduro Biotech Names Industry Veteran And Academic Leader, Gerald Chan, DSc To Its Board Of Directors

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that renowned academic leader and industry veteran, Gerald Chan, DSc has joined its board of directors. Dr. Chan is the co-founder of Morningside, a private investment group with venture, private equity and property investments.

In the life science sector, Morningside focuses on start-up biotechnology companies founded on novel scientific discoveries. Dr. Chan serves on the boards of Advanced Cell Diagnostics, Oxyrane, Stealth Peptides, Synchroneuron, Apellis, Nucana, VTI and Matrivax. 

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.